The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.
 
Shaan Dudani
No Relationships to Disclose
 
Guillermo de Velasco
Honoraria - Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; MSD; Novartis; Pfizer
Research Funding - Ipsen
Other Relationship - Janssen
 
Connor Wells
Travel, Accommodations, Expenses - Pfizer
 
Chun Loo Gan
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
Frede Donskov
Research Funding - Ipsen (Inst); Pfizer (Inst)
 
Camillo Porta
No Relationships to Disclose
 
Anna Fraccon
No Relationships to Disclose
 
Felice Pasini
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - Alteogen; Bristol-Myers Squibb; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Georg A. Bjarnason
Stock and Other Ownership Interests - Merck
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Benoit Beuselinck
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Ipsen (Inst); Pfizer (Inst)
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Takeshi Yuasa
No Relationships to Disclose
 
Nils Kroeger
No Relationships to Disclose
 
Ravindran Kanesvaran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Janssen; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; MSD Oncology; Novartis; pfizer
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; MSD Oncology
 
M. Neil Reaume
Honoraria - AstraZeneca; Ipsen; Novartis; Pfizer
Research Funding - AstraZeneca
 
Christina M. Canil
Honoraria - Janssen
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - Amgen; Pfizer; Sanofi
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)